Resistant hypertension
DOI:
https://doi.org/10.31053/1853.0605.v69.n3.21123Keywords:
HypertensionAbstract
Resistant hypertension, defined as a persistent blood pressure over 140/90 mmHg despite the use of three antihypertensive agents including a diuretic, is unusual. The diagnosis requires ruling out initially pseudoresistance and a deficient compliance with treatment. Ambulatory blood pressure recording allow the recognition of white coat hypertension. When there is a clinical or laboratory suspicion, secondary causes of hypertension should be discarded. Excessive salt intake, the presence of concomitant diseases such diabetes, chronic renal failure, obesity, and psychiatric conditions as panic attacks, anxiety and depression, should also be wanted. The presence of target organ damage requires a more aggressive treatment of hypertension. Recent clinical studies indicate that the administration of aldosterone antagonists as a fourth therapeutic line provides significant additional blood pressure reduction, when added to previous antihypertensive regimens in subjects with resistant hypertension.Downloads
References
Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 108.189 Full Text
Pimenta E, Gaddam KK, Oparil S. Mechanisms and treatment of resistant hypertension. J Clin Hypertens (Greenwich). 2008 Mar;10(3):239-44 Full Text
Pimenta E; Calhoun DA ; Oparil S Mechanisms and treatment of resistant hypertension Arq. Bras. Cardiol. vol.88 no.6 , June 2007 Full text
Nishizaka MK, Zaman MA y Calhoun DA Efficacy of Low-Dose Spironolactone in Subjects with Resistant Hypertension American Journal of Hypertension 16(11):925-930, Nov 2003 PubMed
Marin M Aldosterona e hipertensión arterial. Boletín del Consejo Argentino de H.T.A. - Año 6 - Julio-Diciembre – 2005
de Souza F, Muxfeldt ES, Salles GF Prognostic factors in resistant hypertension: implications for cardiovascular risk stratification and therapeutic management. Expert Rev Cardiovasc Ther. 2012 Jun;10(6):735-45. PubMed
Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007 Apr;49(4):839-45 Full text
Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet. 2012 Aug 11;380(9841):591-600. PubMed
Gassler JP, Lynch PS, Bisognano JD The role of baroreflex activation therapy in sympathetic modulation for the treatment of resistant hypertension. Heart. 2012 Aug 15. PubMed
Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension. 2012 Sep;60(3):596-606 PubMed
Mancia, Giuseppe Additional drug treatment in resistant hypertension: need for randomized studies J Hypertens 2012,30:1514–1515 PubMed
Bobrie, Guillaume; Frank, Michael; Azizi, Michel; Peyrard, Séverine; Boutouyrie, Pierre; Chatellier, Gilles; Laurent, Stéphane; Menard, Joël; Plouin, Pierre-François Sequential nephron blockade versus sequential renin–angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study J Hypertension. 30(8):1656-1664, 2012. PubMed
Downloads
Published
Issue
Section
License
Copyright (c) 2012 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The generation of derivative works is allowed as long as it is not done for commercial purposes. The original work may not be used for commercial purposes.
How to Cite
